Title: Purity of consumer-level methamphetamine samples and methamphetamine-adulteration of other drugs: Los Angeles, 2023-2024

Authors: Adam J. Koncsol, MPA[1]; Caitlin A. Molina, BA, BS[1]; Ruby Romero, BA[1]; Michelle Poimboeuf, MPH[1]; Morgan E. Godvin, BA[1]; Jasmine Feng, BS[1]; Siddarth Puri, MD[2]; Joseph R. Friedman, MD, PhD[3], MPH; Chelsea L. Shover, PhD[1]

(1) University of California, Los Angeles: Division of General Internal Medicine and Health Services Research
(2) San Luis Obispo County Department of Behavioral Health
(3) University of California, San Diego

Abstract:

Background: National trends indicate a rise in both methamphetamine-involved deaths and people living with methamphetamine-use disorders. Reports from the Department of Justice and Drug Enforcement Agency indicate methamphetamine seized during criminal investigations is almost uniformly high purity. However, there remains limited information on the purity of methamphetamine at the consumer level.

Methods: Anonymous participants accessing a community-based drug checking program voluntarily provided samples of illicit drug product and completed brief interviews in Los Angeles County, California from February 2023 to November 2024. Samples underwent laboratory-based qualitative direct analysis in real time mass spectrometry and liquid chromatography mass spectrometry to quantify a panel of twelve substances. Statistical methods were used to determine differences between co-detected substances among samples expected to be methamphetamine and samples where methamphetamine was detected but unexpected.

Results: Of 201 samples expected to be methamphetamine, 88% (n=177) contained only methamphetamine, with the average freebase purity of 68 of those samples being 58%, ranging from 0.1%-96%. Methamphetamine was also detected in 87 samples of other expected drugs, such as fentanyl, MDMA, and heroin.

Conclusion: Methamphetamine tested at the consumer-level was found to primarily contain only methamphetamine, despite heterogeneous and highly variable purity. Methamphetamine was also frequently found to be an adulterant in other substances rather than a target of adulteration, which may indicate unwitting exposure among people intending to use other drugs. Given the physiological and psychological effects of chronic methamphetamine use, future research should expand methamphetamine surveillance techniques and investigate how variability in purity may impact health outcomes.

Introduction / Background:

Methamphetamine use continues to rise around the world, particularly in the Americas, Asia, and Australia (Blemings & Cunningham, 2024; Han, Compton, et al., 2021; Han, Cotto, et al., 2021, p. 2; Hedegaard et al., 2020). In the United States, an estimated 2.0 million people used methamphetamine in 2019, over half of which were people who frequently used methamphetamine, with estimates as high as 1.2% in the Western United States in 2022-2023 (Han, Compton, et al., 2021; SAMHSA Center for Behavioral Health Statistics and Quality, 2025). Methamphetamine-related deaths, including but not limited to overdose deaths involving methamphetamine co-detected with other substances (typically opioids) and methamphetamine-associated cardiac events, have more than quintupled from 2012-2021 in the U.S. (Han, Compton, et al., 2021; Han, Cotto, et al., 2021; Hedegaard et al., 2020; Shover et al., 2023). Deaths involving psychostimulants from about 4,500 deaths in 2015 to over 30,000 as of September 2024 (National Center for Health Statistics, 2025). While methamphetamine does not currently have a specific ICD-10 multiple-cause-of-death code separate from other psychostimulants to be used in classification of death schema, it is typically understood to primarily comprise most records included in code T43.6: *psychostimulants with abuse potential* (United States Sentencing Commission, 2024).

As a synthetic drug, methamphetamine is considerably cheaper and easier to manufacture than agriculturally-derived drugs like cocaine or heroin (Jones et al., 2022; Lewis et al., 2021; Montero et al., 2022). Data from law enforcement seizures and Department of Justice sentencing guidelines reflect a high average purity of methamphetamine, with most recently available national averages exceeding 90% (Drug Enforcement Administration Special Testing and Research Laboratory of the Office of Forensic Science, 2024; Onoka et al., 2020; Toske & McKibben, 2022; United States Sentencing Commission, 2024). However, data on the methamphetamine used by consumers is much more limited. While public health campaigns have largely focused on the threat of methamphetamine adulterated with fentanyl due to rising trends in polysubstance-associated fentanyl overdose deaths (Allen et al., 2023; Drug Enforcement Administration, 2021; Friedman & Shover, 2023; LaRue et al., 2019), there remains limited evidence about methamphetamine adulteration and purity at the street level. Here we leverage data from a community-based drug checking program to characterize the composition of methamphetamine samples tested in Los Angeles, California.

Methods:

Anonymous participants accessing a community-based drug checking program, *Drug Checking Los Angeles*, voluntarily provided samples of illicit drug products for testing at four different sites in Los Angeles County, California (Hollywood, East Los Angeles, Downtown Los Angeles, and South Los Angeles) from February 2023 to November 2024. Information on what the drug was

purported to be at the time of sale, subjective effects (if tried), any possible concerns, and other variables were collected through an anonymous, optional survey conducted by trained drug checking staff. Drug checking and data collection through *Drug Checking Los Angeles* operations were deemed by UCLA's Institutional Review Board as public health surveillance and does not constitute research. Given this classification, the work presented here is not subject to IRB oversight.

Samples were analyzed initially in the field with Fourier-transform infrared (FTIR) spectroscopy and immunoassay test strips. Samples were then sent to the National Institute of Standards and Technology (NIST) for secondary laboratory-based qualitative and quantitative testing using direct analysis in real time mass spectrometry (DART-MS) and liquid-chromatography mass spectrometry (LC-MS). Both FTIR and DART-MS assess samples against libraries of over 1,300 substances, including pharmaceutical and illicit drugs, adulterants, cutting and bulking agents, precursor chemicals, and other substances (e.g., adhesives, food products, etc.). The LC-MS quantification panel included twelve substances: fentanyl and fluorofentanyl, fentanyl precursor chemicals (4-ANPP, phenethyl 4-ANPP), heroin, methamphetamine, cocaine, α_2-agonists (xylazine and medetomidine), and three common fentanyl adulterants (tetracaine, lidocaine, and Bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate (BTMPS) (Shover et al., 2025)). For more detailed descriptions of the confirmatory methodologies employed here, see Appley et al., 2023; Shover et al., 2025.

Descriptive statistics for samples qualitatively tested with DART-MS were calculated to illustrate the co-detection of other substances among samples sold as, or otherwise expected to be, methamphetamine as well as samples where methamphetamine was detected but unexpected (e.g., such as in samples expected to be fentanyl, MDMA, or cocaine) where methamphetamine is functionally an adulterant, hereon referred to as methamphetamine-unexpected samples. Summary statistics were calculated for quantified LC-MS samples, represented as percentage by mass, for both samples expected to be methamphetamine and samples where methamphetamine was unexpectedly detected. Methamphetamine concentration is reported in freebase form, not accounting for the weight of the salt. Welch's *t* tests were conducted to determine the statistical significance of differences between average percentage of methamphetamine among samples expected to be methamphetamine and samples where methamphetamine was detected in other drugs.

Results:

There were N = 297 total samples tested in Los Angeles that contained methamphetamine confirmed by secondary DART-MS testing. Among the 297 total samples detected with methamphetamine using the qualitative DART analysis, n = 210 were bought as or otherwise expected to be methamphetamine (n = 204 samples were expected to contain only

methamphetamine, n = 5 which were expected to be a heroin-methamphetamine or fentanyl-methamphetamine mix (i.e., "goofballs"), n = 1 sample was expected to be a methamphetamine and ketamine mix).

Table 1 shows all co-detected substances (via DART-MS) for both samples expected to be methamphetamine (excluding goofballs) and samples where methamphetamine was detected in other drugs. Of the 201 methamphetamine expected samples, 88% (n=177) solely contained methamphetamine, the remaining 12% (n=24) contained methamphetamine and a different substance. Co-detected substances include ephedrine (n = 8), cocaine (n = 5), fentanyl (n = 3), MDAI (n = 3), N,N-dimethylamphetamine (n = 2), dimethyl sulfone (MSM) (n = 2), acetaminophen (n = 1), benzocaine (n = 1), ketamine (n = 1), levamisole (n = 1), lidocaine (n = 1), MDMA (n = 1), and 6-monoacetylmorphine (n = 1).

Among instances of samples sold as or otherwise expected to be drugs, methamphetamine was found in 8% of expected fentanyl samples (27 of 336 total), 10.5% of expected heroin samples (11 of 105 total), 69.2% of expected-Adderall samples (9 of 13 total), 10% of expected MDMA/MDA samples (8 of 80 total), 29.4% of expected-2C-B samples (5 of 17 total), 9.8% of expected-benzodiazepine samples (4 of 41 total), 2.6% of expected-cocaine samples (2 of 78 total), 40% of expected-BDO/GHB samples (2 of 5 total), 25% of expected "psilocybin" products (2 of 8 total), 2.4% of expected ketamine samples (1 of 41 total), and 2.7% of expected opioid pills (e.g., oxycodone) (1 of 36 total).

Of the 297 total methamphetamine-positive samples, 94 samples were quantitated with the LC-MS panel, where n = 69 samples were bought as or otherwise expected to be methamphetamine and n = 25 samples where that were expected to be a drug other than methamphetamine. Of the 69 quantitated samples expected to be methamphetamine, 68 contained methamphetamine, with an average methamphetamine concentration of 57.9% and a standard deviation of 20.0 (**Table 2**). In the 25 samples where methamphetamine was detected in other drugs, samples were expected to be Adderall (n = 4), BDO (n = 1), cocaine (n = 1), fentanyl (n = 11), heroin (n = 3), and "unknown" samples (n = 5) where drug expectation could not be determined e.g., "ground-scores" (drugs that were found on the ground) or instances where no survey information was provided. Of those 25 methamphetamine-adulterated samples detected on DART-MS, 23 were quantitated with an average methamphetamine concentration of 19.4% and a standard deviation of 28.0 (**Table 2**), with evidence that the mean methamphetamine percentage is significantly different ($\alpha = 0.05$, $p < .001$) in samples expected to be methamphetamine compared to samples which were not expected to contain methamphetamine. **Figure 1** and **Figure 2** help visualize the high range and standard deviation of methamphetamine concentration in quantitated samples.

Discussion

In this study of consumer-level methamphetamine samples, we found that drugs expected to be methamphetamine overwhelmingly (88%) contained only methamphetamine, with freebase purity ranging from 0.1% - 95.9%, mean = 58%, and standard deviation = 20.0. We also found that methamphetamine was regularly detected in samples expected to be other drugs, sometimes at substantial amounts. These findings show that concentration of methamphetamine at the consumer-level is not nearly as uniform or uniquely high-purity as drug seizure data suggest. While the profiling efforts of both the Drug Enforcement Agency and the Department of Justice seem to indicate a drug market very extraordinarily high purity methamphetamine (95%-100%) among large amounts (e.g., 10+ kilos) of product seized during trafficking offenses, our results help to reveal the nature of methamphetamine purity at the end of the supply chain where it matters most: the person using the drug.

Despite the highly variable concentrations of methamphetamine between samples, there is no indication that methamphetamine itself is widely and consistently adulterated, particularly given nearly 90% of methamphetamine samples contained no additional detected compounds besides methamphetamine. In the 24 samples of expected methamphetamine with co-detected substances, 10 contained only non-psychoactive substances: ephedrine (a precursor), dimethylamphetamine (a byproduct of methamphetamine synthesis), dimethyl sulfone (MSM), and acetaminophen—meaning over 93% of expected methamphetamine samples contained either only methamphetamine or methamphetamine and non-psychoactive compounds. While 14 samples were co-detected with psychoactive substances like cocaine, MDAI, MDMA, and ketamine.

Only three expected methamphetamine samples contained fentanyl and only two contained fentanyl above threshold amounts (≈ 0.01% by mass). Of the two methamphetamine samples with above threshold-detectable fentanyl, one sample was a drug residue swab from pipe, which may have previously been used with other substances. While accidental fentanyl exposure still poses an overdose concern for people who are opioid-naïve, the fact that only 1 sample of actual methamphetamine product contained unexpected fentanyl above threshold amounts is somewhat inconsistent with the widespread public health concern that methamphetamine is routinely adulterated with fentanyl in Los Angeles. Nevertheless, these findings are not sufficient to demonstrate this finding is generalizable to wider drug markets, and caution related to fentanyl contamination in stimulants is still warranted.

Among drugs expected to be methamphetamine, the range of methamphetamine concentration in our sample varied highly. This underscores the clinical benefits of understanding a patient's tolerance to methamphetamine when initiating treatment. For example, development and implementation of prescribing guidelines for stimulant replacement therapies should understand that patients are exposed to a wide range of methamphetamine purities. Understanding risks and benefits of different treatment options for methamphetamine toxicity, psychosis, mood

regulation, methamphetamine dependence could greatly be informed by the effect of supply-side methamphetamine purity. Similarly, modification of health behaviors, through for example, treatments that include contingency management that promotes abstention from stimulant use, substance use psychosocial treatment including cognitive behavioral therapy, motivational interviewing and/or the community reinforcement approach, and additional public health interventions that include harm reduction programming may be able to consider that methamphetamine purity varies significantly when suggesting methods to avoid overamping and modifying other risky health behaviors.

Here we find that methamphetamine often serves an adulterant to other substances rather than the target of adulteration. This suggests that unexpected adulteration with methamphetamine may likely be more common than prior literature suggests, indicating that people who use drugs such as fentanyl, heroin, or cocaine may unknowingly be exposed to methamphetamine, which has dangerous unintended consequences. Of note, among samples where methamphetamine is detected in other drugs, it is typically detected at levels which may be clinically significant (μ = 19.4%) and may contribute to physical health and psychiatric signs and symptoms inconsistent with the clinically presentation typical from using opioids or short acting-stimulants (such as cocaine) alone.

Dimethyl sulfone has been previously described as a common methamphetamine adulterant due to its crystalline shape yet was identified in only 1% of our samples. This is particularly striking compared to the DEA's 2022 MPP identification of dimethyl sulfone in 19% of methamphetamine samples in California (Drug Enforcement Administration Special Testing and Research Laboratory of the Office of Forensic Science, 2024).

The number of people who use both fentanyl and methamphetamine, either sequentially, or at the same time in a mixture (colloquially known as a "goofball"), has been growing (Bluthenthal et al., 2015; Glick et al., 2021; Hazani et al., 2022; Ivsins et al., 2022). However, there is limited evidence describing if the substances are often intentionally sold together, and if so, if buyers are aware that they are purchasing a polysubstance mixture. There is also limited evidence to support the notion that fentanyl is routinely intentionally added to samples sold as methamphetamine, particularly given the high purity of reported methamphetamine seizure data and lack of any significant mention of any opioid contamination (Drug Enforcement Administration Special Testing and Research Laboratory of the Office of Forensic Science, 2024; Onoka et al., 2020; Toske & McKibben, 2022). However, fentanyl adulteration of stimulants continues to attract significant attention from law enforcement and public health communities (Drug Enforcement Administration, 2024, p. 34).

While methamphetamine samples tested through a community-based drug checking program can provide unique insights into consumer-level drug markets, there are several limitations to

consider. Co-detection could occur through cross-contamination of substances prior to being checked (e.g., storing multiple drug products in the same bag). Convenience bias may also affect the generalizability of the sample given that drugs were largely only checked at four sites in the greater Los Angeles region and that samples brought to be checked may be systematically different than those which were not (e.g. some people bring only samples to check after an adverse or unusual experience). Field-based and laboratory methods are subject to various errors that may affect the precision of our estimates, including margin of error in quantification and limitations of specific analytical methods. For example, DART-MS techniques were not generally equipped to detect large molecules, so the prevalence of large-molecule adulterants such as sugars may be underestimated in these results. FTIR is generally insensitive to detect compounds that make up a very low portion of a substance's mass, so adulterants that were not primary components may have been underestimated. Finally, the LC-MS panel included only a small number of potential compounds, so items not on this list were not quantified. We aimed to mitigate some of these limitations via use of multiple technologies, yet results should be interpreted in light of these potential sources of error.

Conclusion:

Understanding methamphetamine concentration among drug samples in the community has a number of clinical and public health implications. Public health surveillance of consumer-level drug market makeup and trends allows for both those in clinical medicine and public health to respond to and prepare for the challenges involved with population-wide increases in methamphetamine use. Future research should explore methamphetamine concentration at the consumer level in other contexts outside of Los Angeles and the southwestern USA more generally. Further research is warranted to understand methamphetamine as an adulterant and the health effects of consuming other drugs adulterated with methamphetamine needs to be conducted.

Table 1: Prevalence (count and percent) of co-detected substances of methamphetamine-involved samples among samples of expected methamphetamine and methamphetamine detected in other drugs, N = 288

	Methamphetamine-unexpected samples: n = 87		Methamphetamine-expected samples: n = 201		X^2 test: p-value
Substance	*n*	*% of group*	*n*	*% of group*	
Fentanyl	32	36.8%	3	1.5%	< .001
4-ANPP	23	26.4%	0	0.0%	< .001
Acetaminophen	15	17.2%	1	0.5%	< .001
Heroin	11	12.6%	0	0.0%	< .001
Lidocaine	9	10.3%	1	0.5%	< .001
6-monoacetylmorphine	8	9.2%	1	0.5%	< .001
Cocaine	8	9.2%	5	2.5%	0.012
Mannitol	7	8.0%	0	0.0%	< .001
2C-B	6	6.9%	0	0.0%	< .001
Aniline	6	6.9%	0	0.0%	< .001
BTMPS	6	6.9%	0	0.0%	< .001
Ketamine	6	6.9%	1	0.5%	0.001
Papaverine	6	6.9%	0	0.0%	< .001
Phenethyl 4-ANPP	6	6.9%	0	0.0%	< .001
Xylazine	6	6.9%	0	0.0%	< .001
Caffeine	4	4.6%	0	0.0%	0.002
Fluorofentanyl	4	4.6%	0	0.0%	0.002
6-acetylcodeine	3	3.4%	0	0.0%	0.008
Noscapine	3	3.4%	0	0.0%	0.008
Unidentified: MZ-384	3	3.4%	0	0.0%	0.008
Alprazolam	2	2.3%	0	0.0%	0.031
Despropionyl Fluorofentanyl	2	2.3%	0	0.0%	0.031
NPP	2	2.3%	0	0.0%	0.031
Norfentanyl	2	2.3%	0	0.0%	0.031
2C-H	1	1.1%	0	0.0%	0.128
4-Piperidone	1	1.1%	0	0.0%	0.128
Benzoylecgonine	1	1.1%	0	0.0%	0.128
Cannabidiol (CBD)	1	1.1%	0	0.0%	0.128
Cannabinol (CBN)	1	1.1%	0	0.0%	0.128
Dimethyl Sulfone (MSM)	1	1.1%	2	1.0%	0.906
Levamisole	1	1.1%	1	0.5%	0.541
MDA	1	1.1%	0	0.0%	0.128
Methadone	1	1.1%	0	0.0%	0.128
N-phenethyl-N-phenylpropionamide	1	1.1%	0	0.0%	0.128

N,N-dimethylamphetamine	1	1.1%	2	1.0%	0.906
Benzocaine	0	0.0%	1	0.5%	0.51
Ephedrine	0	0.0%	8	4.0%	0.059
MDAI	0	0.0%	3	1.5%	0.252

Note: Table shows count and percentage (of total) of substances co-detected with methamphetamine-involved samples, among expected methamphetamine and unexpected methamphetamine. N = 288 samples where methamphetamine was qualitatively detected using DART-MS. n = 5 samples expected to be goofballs (i.e., a mix of both methamphetamine and heroin / fentanyl) were excluded. Of the 87 expected non-methamphetamine samples, participants expected fentanyl (n = 27), heroin (n = 11), Adderall (n = 9), MDMA or MDA (n = 8), 2C-B (n = 5), benzodiazepines (n = 4), cocaine (n = 2), BDO or GHB (n = 2), psilocybin mushroom chocolates and gummies (n = 2), ketamine (n = 1), opioid pills (e.g., Oxycontin) (n = 1), cannabis (n = 1)) as well as "unknown" samples (n = 14) where drug expectation could not be determined (e.g., "ground-scores"). A Pearson X^2 test shows the co-detection of many substances is significantly different varied by whether a drug product was purchased as or otherwise expected to be methamphetamine or not. The most common co-detected substances among drug products expected to be methamphetamine are ephedrine (4.0%) and cocaine (2.5%). 88% (n = 177) of samples expected to be methamphetamine had only methamphetamine and no other compounds detected.

Table 2: Average concentration (percent by mass) of methamphetamine-involved samples among samples of expected methamphetamine and unexpected methamphetamine, N = 94

Substance	**Methamphetamine-unexpected samples:** ***mean; (SD); n; min – max***	**Methamphetamine-expected samples:** ***mean; (SD) n; min – max***	**Welch's *t* test p-value**
Methamphetamine	19.37%	57.92%	$p < .001$
	(27.96)	(19.98)	
	n = 25	n = 68	
	0.1% - 81.9%	0.1 - 95.93%	
Fentanyl	3.62%		
	(2.69)		
	n = 10		
	0.65% - 7.91%		
Fluorofentanyl	1.09%		
	(1.40)		
	n = 3		
	0.1% - 2.7%		
4-ANPP	0.47%		
	(0.34)		
	n = 7		
	0.1% - 1.01%		
Phenethyl 4-ANPP	0.1%		
	(0)		
	n = 3		
	0.1%		
Xylazine	5.88%		
	(11.46)		
	n = 4		
	0.1% - 23.07%		
BTMPS	1.77%		
	(1.53)		
	n = 6		
	0.1% - 4.59%		
Cocaine	13.35%		
	(13.76)		
	n = 2		
	3.6% - 23.07%		
Lidocaine	2.27%		
	(1.01)		
	n = 6		
	0.4% - 2.93%		

Heroin	32.00% (40.84) n = 4 0.1 – 86.33%		
Total	n = 25	n = 68	

Note: Table shows the count, mean, and range concentration(s) (percentage by mass) of methamphetamine-involved samples, among (a) samples bought as or otherwise expected to be methamphetamine and (b) samples bought as or otherwise expected to not-methamphetamine. Methamphetamine concentration is reported as freebase form, not accounting for the weight of the salt. N = 94 samples where methamphetamine was detected and quantified using LC/MS. Expected non-methamphetamine samples include Adderall (n = 4), BDO (n = 1), cocaine (n = 1), fentanyl (n = 11), heroin (n = 3) as well as "unknown" samples (n = 5) where drug expectation could not be determined (e.g., "ground-scores"). Among expected methamphetamine samples, methamphetamine was the only substance detected in the LC/MS panel. A Welch's *t*-test shows the average concentration of methamphetamine is significantly different ($p < .001$) according to whether methamphetamine was the expected drug or if it was a drug adulterated with methamphetamine. Drug product samples were collected through a community-based drug checking program in Los Angeles from February 2023 – November 2024.

Fig 1: Average concentration of quantified compounds in samples, stratified by expected contents



Figure shows concentration (percentage by mass) of methamphetamine-involved samples, among (a) samples bought as or otherwise expected to be methamphetamine and and (b) samples bought as or otherwise expected to not-methamphetamine. N = 94 samples where methamphetamine was detected and quantified using LC/MS. Drug product samples were collected through a community-based drug checking program in Los Angeles from February 2023 – November 2024.

Fig 2: Distribution of methamphetamine concentration among samples expected to be and not be methamphetamine, N = 94



Note: Figure shows distribution of methamphetamine concentration (percent by mass) of methamphetamine-involved samples for (a) samples bought as or otherwise expected to be methamphetamine and (b) samples bought as or otherwise expected to not-methamphetamine. Drug product samples were collected through a community-based drug checking program in Los Angeles from February 2023 – November 2024.

Reference:

Allen, C., Arredondo, C., Dunham, R., Fishman, M., Lev, L., Mace, S., Parks, J., Rosa, D., Shoyinka, S., White, D., & Williams, A. (2023). Guidance for Handling the Increasing Prevalence of Drugs Adulterated or Laced With Fentanyl. *Psychiatric Services*, *74*(10), 1059–1062. https://doi.org/10.1176/appi.ps.202100660

Appley, M. G., Robinson, E. L., Thomson, A., Russell, E., & Sisco, E. (2023). An analytical platform for near real-time drug landscape monitoring using paraphernalia residues. *Forensic Chemistry*, *34*, 100489. https://doi.org/10.1016/j.forc.2023.100489

Blemings, B., & Cunningham, S. (2024). Temporary gains and permanent costs in methamphetamine precursor control. *International Journal of Drug Policy*, 104501. https://doi.org/10.1016/j.drugpo.2024.104501

Bluthenthal, R. N., Wenger, L., Chu, D., Lorvick, J., Quinn, B., Thing, J. P., & Kral, A. H. (2015). Factors associated with being asked to initiate someone into injection drug use. *Drug and Alcohol Dependence*, *149*, 252–258. https://doi.org/10.1016/j.drugalcdep.2015.02.011

Drug Enforcement Administration. (2021). *DEA Issues Public Safety Alert on Sharp Increase in Fake Prescription Pills Containing Fentanyl and Meth*. https://www.dea.gov/press-releases/2021/09/27/dea-issues-public-safety-alert

Drug Enforcement Administration. (2024). *National Drug Threat Assessment 2024* (DEA-DCT-DIR-010-24; pp. 1–57). https://www.dea.gov/sites/default/files/2024-05/NDTA_2024.pdf

Drug Enforcement Administration Special Testing and Research Laboratory of the Office of Forensic Science. (2024). *Methamphetamine Profiling Program Report: CY 2022* (PRB# 2024-02). https://www.dea.gov/documents/2024/2024-09/2024-09-11/cy-2022-methamphetamine-profiling-program-report

Friedman, J., & Shover, C. L. (2023). Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021. *Addiction (Abingdon, England)*, *118*(12), 2477–2485. https://doi.org/10.1111/add.16318

Glick, S. N., Klein, K. S., Tinsley, J., & Golden, M. R. (2021). Increasing Heroin-Methamphetamine (Goofball) Use and Related Morbidity Among Seattle Area People Who Inject Drugs. *The American Journal on Addictions*, *30*(2), 183–191. https://doi.org/10.1111/ajad.13115

Han, B., Compton, W. M., Jones, C. M., Einstein, E. B., & Volkow, N. D. (2021). Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. *JAMA Psychiatry*, *78*(12), 1329. https://doi.org/10.1001/jamapsychiatry.2021.2588

Han, B., Cotto, J., Etz, K., Einstein, E. B., Compton, W. M., & Volkow, N. D. (2021). Methamphetamine Overdose Deaths in the US by Sex and Race and Ethnicity. *JAMA Psychiatry*, *78*(5), 564. https://doi.org/10.1001/jamapsychiatry.2020.4321

Hazani, H. M., Naina Mohamed, I., Muzaimi, M., Mohamed, W., Yahaya, M. F., Teoh, S. L., Pakri Mohamed, R. M., Mohamad Isa, M. F., Abdulrahman, S. M., Ramadah, R., Kamaluddin, M. R., & Kumar, J. (2022). Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail. *Frontiers in Pharmacology*, *13*, 859563. https://doi.org/10.3389/fphar.2022.859563

Hedegaard, H., Miniño, A., & Warner, M. (2020). Drug Overdose Deaths in the United States, 1999–2018. *NCHS Data Brief*, *356*.

Ivsins, A., Fleming, T., Barker, A., Mansoor, M., Thakarar, K., Sue, K., & McNeil, R. (2022). The practice and embodiment of "goofballs": A qualitative study exploring the co-injection of methamphetamines and opioids. *International Journal of Drug Policy*, *107*, 103791. https://doi.org/10.1016/j.drugpo.2022.103791

Jones, C. M., Houry, D., Han, B., Baldwin, G., Vivolo-Kantor, A., & Compton, W. M. (2022). Methamphetamine use in the United States: Epidemiological update and implications for prevention, treatment, and harm reduction. *Annals of the New York Academy of Sciences*, *1508*(1), 3–22. https://doi.org/10.1111/nyas.14688

LaRue, L., Twillman, R. K., Dawson, E., Whitley, P., Frasco, M. A., Huskey, A., & Guevara, M. G. (2019). Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine. *JAMA Network Open*, *2*(4), e192851. https://doi.org/10.1001/jamanetworkopen.2019.2851

Lewis, D., Kenneally, M., Van denHeuvel, C., & Byard, R. W. (2021). Methamphetamine deaths: Changing trends and diagnostic issues. *Medicine, Science and the Law*, *61*(2), 130–137. https://doi.org/10.1177/0025802420986707

Montero, F., Bourgois, P., & Friedman, J. (2022). Potency-Enhancing Synthetics in the Drug Overdose Epidemic: Xylazine ("Tranq"), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and Tijuana. *Journal of Illicit Economies and Development*, *4*(2), 204–222. https://doi.org/10.31389/jied.122

National Center for Health Statistics. (2025, February 4). *Provisional Drug Overdose Data*. Vital Statistics Rapid Release. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Onoka, I., Banyika, A. T., Banerjee, P. N., Makangara, J. J., & Dujourdy, L. (2020). A review of the newly identified impurity profiles in methamphetamine seizures. *Forensic Science International: Synergy*, *2*, 194–205. https://doi.org/10.1016/j.fsisyn.2020.06.004

SAMHSA Center for Behavioral Health Statistics and Quality. (2025). *National Surveys on Drug Use and Health, 2022 and 2023*. [Dataset]. https://www.samhsa.gov/data/sites/default/files/reports/rpt56185/2023-nsduh-sae-tables-percents/2023-nsduh-sae-tables-percent.xlsx

Shover, C. L., Friedman, J. R., Romero, R., Buhr, R., Chu, B., Tang, A., Medina, J. A., Wisk, L., Lucas, J., & Goodman-Meza, D. (2023). Longitudinal changes in co-involved drugs, comorbidities,

and demographics of methamphetamine-related deaths in Los Angeles County. *Journal of Substance Use & Addiction Treatment*, *151*. https://doi.org/10.1016/j.josat.2023.209101

Shover, C. L., Godvin, M. E., Appley, M., Pyfrom, E. M., Castrillo, F. M., Hochstatter, K., Nadel, T., Garg, N., Koncsol, A., Friedman, J. R., Molina, C. A., Romero, R., Harshberger, B., Gonzalez, J. A. M., Spoliansky, J., Laurel, S., Jalayer, E., Ruelas, J., Gonzales, J., … Sisco, E. (2025). UV Stabilizer BTMPS in the Illicit Fentanyl Supply in 9 US Locations. *JAMA*, e2427550. https://doi.org/10.1001/jama.2024.27550

Toske, S. G., & McKibben, T. D. (2022). Monitoring methamphetamine in the United States: A two-decade review as seen by the DEA methamphetamine profiling program. *Drug Testing and Analysis*, *14*(3), 416–426. https://doi.org/10.1002/dta.3186

United States Sentencing Commission. (2024, June 10). *Methamphetamine Trafficking Offenses in the Federal Criminal Justice System*. United States Sentencing Commission. https://www.ussc.gov/research/research-reports/methamphetamine-trafficking-offenses-federal-criminal-justice-system

Fig 1: Average concentration of quantified compounds in samples, stratified by expected contents



Figure shows concentration (percentage by mass) of methamphetamine−involved samples, among (a) samples bought as or otherwise expected to be methamphetamine and and (b) samples bought as or otherwise expected to not−methamphetamine. N = 94 samples where methamphetamine was detected and quantified using LC/MS. Drug product samples were collected through a community−based drug checking program in Los Angeles from February 2023 ? November 2024.

Fig 2: Distribution of methamphetamine concentration among samples expected to be and not be methamphetamine, N = 94



Note: Figure shows distribution of methamphetamine concentration (percent by mass) of methamphetamine−involved samples for (a) samples bought as or otherwise expected to be methamphetamine and (b) samples bought as or otherwise expected to not−methamphetamine. Drug product samples were collected through a community−based drug checking program in Los Angeles from February 2025 ? November 2024.